FREE subscription to Science magazines
 
 

FREE NewsBrief


Read the latest NewsBrief

RSS Feed

Get the Scientist Live RSS Feed
RSS Feed



ITCM is a global manufacturer and leading innovator in customised machinery and systems for pharmaceutical packaging and processing.


Landauer specialist cosmetic surgery and weight loss surgery Providers of surgery from breast enlargement to liposuction across the UK
eLab - Latest Issue

 View digital magazine
 

Spectroscopy

Contact-free analysis of chemical substances

Processes at the surface of catalysts

Imaging

Simultaneous imaging and photodynamic therapy of cancer

Using 3D imaging to improve the lives of lung disease patients

Dentistry

Pufferfish at the `beak´ of evolution

Incisive research links teeth with diet

Cell Cultures

Fruit flies provide new knowledge about uninhibited cell growth

Stem cell researchers map new knowledge about insulin production

Automation

An environmentally friendly robot

3D characterization of powder gas stream improves process quality in laser material deposition

Process Technology

Ultra-short laser pulses for science and industry

New graphene-based material could revolutionise electronics industry

Previous eurolab editions

June 2011

December 2010

June 2010

Pharmacology

TNO and Seventh Wave sign letter of intent

TNO, a Dutch contract research organization, and Seventh Wave, an American organization for contract research and consultancy, announce that the companies have signed a letter of intent with regard to TNO's dynamic in vitro gastrointestinal models "TIM". The letter of intent proposes a collaboration in which Seventh Wave will obtain two TIM systems for commercialization in North America. The TIM systems will be used to determine the behavior of oral drug products and drug substances during passage through the gastrointestinal tract.

According to the terms stated in the letter of intent, TNO will supply its proprietary gastrointestinal models to Seventh Wave Laboratories, located in Chesterfield, Missouri. This central U.S. location, coupled with Seventh Wave's customer responsiveness, will shorten study turnaround time for customers in North America. The TIM system has been validated for use in preclinical drug development. Both parties expect the TIM systems to be installed and ready for use by customers in the first quarter of 2010. In addition to the collaboration on the current models, the partners envisage joint projects to further validate the TIM system for new applications.

Niek Snoeij, CEO of TNO Quality of life, explains the benefits of the proposed collaboration as follows: "The partnership with Seventh Wave allows us to capitalize on the strengths of the TIM system and offer extra capacity, flexibility, and faster turn-around times."

John Sagartz, President and CEO of Seventh Wave, adds: "TIM compliments our current preclinical and clinical services. With the TIM system available on site, we have another valuable tool to solve our customers' specific needs in formulation development and pharmacokinetics."
TNO gastroIntestinal Model (TIM)
By simulating accurately the human conditions in the gastrointestinal tract, the TIM system gives insight into the release, solubility, and availability for absorption of pharmaceuticals. This state-of-the-art, validated system has a much higher predictive value than regular dissolution tests. The computer-regulated model can simulate various physiologic states and helps scientists determine the bioaccessibility of active compounds and predict resultant blood concentration after single or repeated intake of various dosage forms.

 

Scientist Live

©2012 Setform Limited

Site By OWB